Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
PODCAST | Product Development

CRISPR lessons; plus AbbVie enters obesity — a BioCentury podcast

BioCentury’s editors also discuss recommendations for early stage rare disease drug development

March 4, 2025 12:45 AM UTC

The track record of biotechs launched to create curative therapies using CRISPR-Cas9 provides new insights into the old debate over whether platform companies should validate their technology on established targets or pursue new ones. On the latest BioCentury This Week podcast, BioCentury’s editors discuss the lessons learned by this small group of companies since their launch a decade ago.

They also discuss the entrance of AbbVie Inc. (NYSE:ABBV) into the obesity race via a $350 million deal with Gubra A/S (CSE:GUBRA) for a clinical stage amylin agonist — does it signal AbbVie’s belief in amylin monotherapy, or will the company be hunting for more obesity assets? The editors also talk about recommendations to streamline the early-stage development of rare disease therapies in the U.S.

BCIQ Company Profiles

Abbvie Inc.

Gubra A/S

BCIQ Target Profiles

Amylin receptor